Tazorac

• Fibrinolytic Agents
• Platelet Aggregation Inhibitors
• ATC:B01AC05

• Tazarotene [USAN:INN]
• Tazorac
• Zorac

• No information avaliable

C₁₄H₁₄ClNS

http://www.rxlist.com/cgi/generic/ticlop.htm

Tazorac FDA

Tazorac MSDS

No information avaliable

263.786 g/mol

No information avaliable

Freely soluble

Solid

3.46

Tablets (for oral administration, containing 250 mg of ticlopidine hydrochloride)

Used to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke.

Ticlopidine is a platelet aggregation inhibitor structurally and pharmacologically similar to clopidogrel. When taken orally, ticlopidine causes a time- and dose-dependent inhibition of both platelet aggregation and release of platelet granule constituents, as well as a prolongation of bleeding time. The intact drug has no significant in vitro activity at the concentrations attained in vivo; and, although analysis of urine and plasma indicates at least 20 metabolites, no metabolite which accounts for the activity of ticlopidine has been isolated.

Absorption is greater than 80%. Food increases absorption.

Single oral doses of ticlopidine at 1600 mg/kg and 500 mg/kg were lethal to rats and mice, respectively. Symptoms of acute toxicity were GI hemorrhage, convulsions, hypothermia, dyspnea, loss of equilibrium and abnormal gait.

Humans and other mammals